1. 900. Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen (TBR) in Maintaining Virologic Suppression Through 144 Weeks (TANGO Study). (4th December 2021) Authors: Osiyemi, Olayemi; Ajana, Faïza; Bisshop, Fiona; De Wit, Stéphane; Portilla, Joaquín; Routy, Jean-Pierre; Wyen, Christoph; Ait-Khaled, Mounir; Pappa, Keith; Wang, Ruolan; Leone, Peter; Wright, Jonathan; Wynne, Brian; van Wyk, Jean A; Aboud, Michael; Smith, Kimberly Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S541 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 900. Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen (TBR) in Maintaining Virologic Suppression Through 144 Weeks (TANGO Study). (4th December 2021) Authors: Osiyemi, Olayemi; Ajana, Faïza; Bisshop, Fiona; De Wit, Stéphane; Portilla, Joaquín; Routy, Jean-Pierre; Wyen, Christoph; Ait-Khaled, Mounir; Pappa, Keith; Wang, Ruolan; Leone, Peter; Wright, Jonathan; Wynne, Brian; van Wyk, Jean A; Aboud, Michael; Smith, Kimberly Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S541 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine. (1st June 2021) Authors: van Wyk, Jean; Ait-Khaled, Mounir; Santos, Jesus; Scholten, Stefan; Wohlfeiler, Michael; Ajana, Faïza; Jones, Bryn; Nascimento, Maria-Claudia; Tenorio, Allan R.; Smith, Don E.; Wright, Jonathan; Wynne, Brian Journal: Journal of acquired immune deficiency syndromes Issue: Volume 87:Number 2(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study. (1st June 2021) Authors: van Wyk, Jean; Ait-Khaled, Mounir; Santos, Jesus; Scholten, Stefan; Wohlfeiler, Michael; Ajana, Faïza; Jones, Bryn; Nascimento, Maria-Claudia; Tenorio, Allan R.; Smith, Don E.; Wright, Jonathan; Wynne, Brian Journal: Journal of acquired immune deficiency syndromes Issue: Volume 87:Number 2(2021) Page Start: 794 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study. (6th January 2020) Authors: van Wyk, Jean; Ajana, Faïza; Bisshop, Fiona; De Wit, Stéphane; Osiyemi, Olayemi; Portilla Sogorb, Joaquín; Routy, Jean-Pierre; Wyen, Christoph; Ait-Khaled, Mounir; Nascimento, Maria Claudia; Pappa, Keith A; Wang, Ruolan; Wright, Jonathan; Tenorio, Allan R; Wynne, Brian; Aboud, Michael; Gartland, ... Journal: Clinical infectious diseases Issue: Volume 71:Number 8(2020) Page Start: 1920 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial . (25th January 2022) Authors: Osiyemi, Olayemi; De Wit, Stéphane; Ajana, Faïza; Bisshop, Fiona; Portilla, Joaquín; Routy, Jean Pierre; Wyen, Christoph; Ait-Khaled, Mounir; Leone, Peter; Pappa, Keith A; Wang, Ruolan; Wright, Jonathan; George, Nisha; Wynne, Brian; Aboud, Michael; van Wyk, Jean; Smith, Kimberly Y Journal: Clinical infectious diseases Issue: Volume 75:Number 6(2022) Page Start: 975 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Hypogonadism: a neglected comorbidity in young and middle-aged HIV-positive men on effective combination antiretroviral therapy. (1st July 2022) Authors: Lachâtre, Marie; Pasquet, Armelle; Ajana, Faïza; Soudan, Benoit; Quertainmont, Yann; Lion, Georges; Durand, Emmanuel; Bocket, Laurence; Mole, Martine; Cornavin, Pauline; Catalan, Pilartxo; Senneville, Éric; Goujard, Cécile; Boufassa, Faroudy; Cheret, Antoine Journal: AIDS Issue: Volume 36:Number 8(2022) Page Start: 1061 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Increased Risk of Serious Bacterial Infections Due to Maternal Immunosuppression in HIV-Exposed Uninfected Infants in a European Country. (22nd July 2014) Authors: Taron-Brocard, Clement; Le Chenadec, Jerome; Faye, Albert; Dollfus, Catherine; Goetghebuer, Tessa; Gajdos, Vincent; Labaune, Jean-Marc; Perilhou, Anais; Mandelbrot, Laurent; Blanche, Stephane; Warszawski, Josiane; Mandelbrot, Laurent; Crenn-Hebert, Catherine; Floch-Tudal, Corinne; Mazy, Fabienne;... Journal: Clinical infectious diseases Issue: Volume 59:Number 9(2014:May 01) Page Start: 1332 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Issue 11 (November 2021) Authors: Jaeger, Hans; Overton, Edgar T; Richmond, Gary; Rizzardini, Giuliano; Andrade-Villanueva, Jaime Federico; Mngqibisa, Rosie; Hermida, Antonio Ocampo; Thalme, Anders; Belonosova, Elena; Ajana, Faïza; Benn, Paul D; Wang, Yuanyuan; Hudson, Krischan J; Español, Carlos Martín; Ford, Susan L; Crauwels, ... Journal: Lancet Issue: Volume 8:Issue 11(2021) Page Start: e679 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial. (28th June 2022) Authors: Chéret, Antoine; Bauer, Rebecca; Meiffrédy, Vincent; Lopez, Pauline; Ajana, Faïza; Lacombe, Karine; Morlat, Philippe; Lascoux, Caroline; Reynes, Jacques; Calin, Ruxandra; Abel, Sylvie; Goujard, Cécile; Rouzioux, Christine; Avettand-Fenoel, Véronique; Meyer, Laurence Journal: Journal of antimicrobial chemotherapy Issue: Volume 77:Number 9(2022) Page Start: 2506 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗